Lymphocyte differentiation antigen CD38 — Drug Target
3 drugs
2 marketed
All drugs that target Lymphocyte differentiation antigen CD38 — marketed and clinical-stage. Includes 2 drug classes acting on this target.
Drug classes
CD38-directed Cytolytic Antibody [EPC] · CD38-directed Cytolytic Antibody
Marketed (2)
- Darzalex · Shanghai Henlius Biotech · Oncology
- SARCLISA · SANOFI AVENTIS US · CD38-directed Cytolytic Antibody [EPC] · Oncology